Ginkgo Bioworks Holdings, Inc.DNA

Ginkgo Bioworks Holdings, Inc. posted $19.5 million in revenue from contracts with customers for the quarter ending 31 March 2026, a figure that sounds healthier than it feels once you note the company also burned $46.7 million in operating cash and posted a net loss of $82.6 million in the same period. The company’s cash and cash equivalents sat at $143.9 million on 31 March 2026, a sum that would buy roughly 1.8 Airbus A320neos at list price-hardly the war chest you’d expect from a company pitching itself as the operating system for biology.

Ginkgo’s platform story is a slick affair: Catalyst ACS schedules the chaos, Catalyst Data harmonises the noise, and Catalyst Agent sits there, nodding along like a very expensive intern, while RACs and Tiles promise high uptime and throughput in high-mix labs. The company even claims it has extensively used its own product internally, which is either impressive or a sign that the automation hasn’t yet scaled beyond the corporate demo room. The website’s hero images show tidy corridors and polished floors, the visual equivalent of a startup that has never had to share a printer.

The quarter’s headline filings are brutal: operating loss of $71.4 million, research and development spend of $49.9 million, and a diluted net loss per share of $5.64 for the year ending 31 December 2025. The company’s assets totalled $1.03 billion, but liabilities were $589.9 million, leaving stockholders’ equity at $443.2 million-solid on paper, but paper thin once you compare it to the quarterly cash burn. The company spent just $1.9 million on property, plant, and equipment in the quarter, a figure so small it reads like a rounding error rather than a scaling story.

If you want to see the platform in action, Ginkgo points to a completed program with Biogen to boost productivity of gene therapy manufacturing, complete with a corporate photo that looks like a lab from a glossy tech brochure. The image is captioned with the claim that Ginkgo is the only automation provider that has extensively used its own product internally-a statement that is either a differentiator or a sign that the product hasn’t yet escaped the pilot phase. The company’s support page promises that its Apex Support service proactively resolves system errors without requiring alerts from users, a claim that sounds like the difference between a concierge and a helpdesk, but the filing reality is still a company haemorrhaging cash and issuing equity to keep the lights on.

The governance filings tell a quieter story: a flurry of Form 4s in June and July 2026 document routine share sales by insiders, while the diluted weighted average shares outstanding sat at 55.5 million as of 31 December 2025. The polished platform story is all about scaling biology’s future, but the filing reality is a company that is still haemorrhaging cash, issuing equity, and hoping its software and hardware mojo will outrun the quarterly income statement. The gap between the pitch and the payroll is wider than a lab bench in a pandemic.

For now, Ginkgo’s sales pitch is a siren song of productivity and promise, but the filings are the map: $19.5 million in revenue, $82.6 million in net losses, and a cash pile that feels more like a down payment than a balance. The company’s hardware and software pages read like a demo reel, but the income statement is the only source the source directs readers to trust. If the platform’s mojo doesn’t translate into repeatable revenue soon, the lab robots may end up as expensive doorstops in a very tidy corridor.